Kymab to Present Update on Lead Immunocytokine Program KY1043 at Two European Scientific Meetings in November 2019
- KY1043, a bifunctional, PD-L1-based, IL-2Rα (CD25)-directed immunocytokine, binds and blocks the activity of PD-L1 on PD-1 and preferentially stimulates T cells via preferential binding to the high affinity trimeric IL-2abg receptor (CD25/CD122/CD132)
- By engaging with both PD-L1 and IL-2αβγ receptor, KY1043 stimulates potent anti-tumor responses in a T cell tumor killing assay leading to enhanced tumor killing compared to a non-targeted immunocytokines
- In vivo, KY1043 produces rapid, dose-dependent tumor regression of established MC38 tumors
- Pharmacodynamic data indicates that KY1043 can increase CD8+ T cells in the tumor microenvironment with differential activity in the periphery that lead to the expansion of Treg cells
- Expanding data set continues to provide evidence for a dual mechanism-of-action of KY1043 in vitro and in vivo
- Development activities, including regulatory-enabling toxicological studies, are in progress
Cambridge, UK; November 14, 2019: Kymab, a clinical-stage biopharmaceutical company developing antibody-based therapeutics, will be delivering oral presentations detailing an expanding body of evidence for the activity of the company’s novel immunocytokine KY1043 at both the Promise of Interleukin-2 Therapy Congress being held at the Centre international de Conférence Sorbonne Université in Paris, France November 13-16 and the 11th annual PEGS Europe Meeting at the Lisbon Center in Lisbon, Portugal November 18-22. These presentations follow the KY1043 poster presented at the Society of Immunotherapy for Cancer (SITC) 34th Annual Meeting held on November 8, in the United States.